openPR Logo
Press release

Fibroblast Activation Protein Inhibitors Market - Evolving Technology, Trends and Industry Analysis – 2024

01-25-2017 06:41 AM CET | Health & Medicine

Press release from: TMR

Fibroblast Activation Protein Inhibitors Market - Evolving

Fibroblast activation protein (FAP) is a serine protein that is selectively expressed in pathologic sites in the adults making it a target specific site for many therapeutic agents. Fibroblast activation protein (FAP) is expressed during tissue remodeling stage in embryonic development. However, in adults, fibroblast activation protein (FAP) is expressed in specific sites like cancer, arthritis, inflammation, injury, pulmonary fibrosis, etc. Fibroblast activation protein is widely believed to be expressed on stromal fibroblasts of epithelial cancer cells and promotes cancer cell growth and metastasis.

Request a PDF Brochure with Report Analysis: http://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=14159

The specificity of fibroblast activation protein offers potential to represent as a new drug target in the diagnosis and treatment of cancer. Various clinical trials are being conducted to assess the potential of treating cancer by inhibiting the fibroblast activation protein. Cancer cells are often very sensitive to growth factors. Development of cancer growth impeders such as fibroblast activation protein (FAP) inhibitors can provide promising results in cancer management.

Fibroblast activation protein (FAP) have similar specificity as dipeptidyl peptidases (DPPs) and prolyl oligopeptidase (PREP) which are also known to elevate in cancers. This leads to the need of development of inhibitors that are specific to fibroblast activation protein (FAP).

Huge opportunities lie in development of fibroblast activation protein (FAP) specific inhibitors. Vigorous research and development programs are being conducted for the development of such inhibitors. One such inhibitor is Val-boroPro (Talabostat) which is a single-agent inhibitor of fibroblast activation protein (FAP) enzymatic activity.

A number of clinical trials have been conducted to assess the efficacy of talabostat as fibroblast activation protein (FAP) inhibitor in different cancers such as colorectal, lung, pancreatic, leukemia and melanoma. Another approach being used in developing fibroblast activation protein (FAP) inhibitor is monoclonal antibodies. However, such approaches have not been extensively used in the clinical setting, mainly due to absence of effective actions.

Due to the rise in the prevalence of cancer globally, fibroblast activation protein (FAP) inhibitors are anticipated to assist in prevention of proliferation of these carcinogenic cells. According to the National Cancer Institute, an estimated 1,685,210 new cases of cancer will be detected in 2016 in the U.S alone. The most common ones are breast cancer, prostate cancer, colon and rectum cancer, lung and bronchus cancer, bladder cancer, melanoma, kidney and renal pelvis cancer, leukemia, and pancreatic cancer.

Of these colorectal cancer is the third most common type of cancer in the world. This cancer is a result of uninhibited cell progression that occurs in the appendix, colon, and the rectum region. The common symptoms of colorectal cancer are bleeding in the stool, weight loss, fatigue, and irregular bowel movements. According to the World Cancer Research Fund International, approximately 1.5 million new cases of colorectal cancer are detected each year. Many clinical trials are being conducted to discover novel methods to treat colorectal cancer through fibroblast activation protein (FAP) inhibitors.

The increasing worldwide prevalence of various cancers, including breast cancer, colorectal cancer, prostate cancer, skin cancer, blood cancer, gastrointestinal tract cancer, and lung cancer, is the prime factor heightening the demand for anti-cancer drugs. In addition to this, the improvement of advanced therapeutic approaches, such as targeted therapies, immunotherapy, radiotherapy, and chemotherapy has significantly benefited the anti-cancer drugs market in recent years.

Browse Full Research Report: http://www.transparencymarketresearch.com/fibroblast-activation-protein-inhibitors-market.html

Although not much progress has been made in fibroblast activation protein (FAP) inhibitors discovery for treating various cancer, this field possesses huge research and development opportunities in the near future.

About Us

Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information. Our business offerings represent the latest and the most reliable information indispensable for businesses to sustain a competitive edge.

Contact Us

Transparency Market Research
State Tower,
90 State Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Fibroblast Activation Protein Inhibitors Market - Evolving Technology, Trends and Industry Analysis – 2024 here

News-ID: 420323 • Views: 226

More Releases from TMR

Dried Herbs Market to Grow at CAGR 4.7%, Food Processing Industry to Fuel Growth
Transparency Market Research illustrates the competitive market in the dried herb industry including The Kraft Heinz Company, Mountain Rose Herbs, Van Drunen Farms, Robertet SA, and Pacific Botanicals. There are several players in the competitive and fragmented global dried herbs market. The manufacturing companies are concentrating on introducing organic herbs due to growing consumer awareness about natural ingredients. These manufacturers are also integrating different strategies to dry herbs without affecting
Coconut Milk Products Market Expected to Expand at a CAGR of 6.9% in Terms of Re …
With reference to the latest market forecast report published by Transparency Market Research, on the title, ‘Coconut Milk Products Market: Global Industry Analysis and Opportunity Assessment 2018-2026’, revenue generated from the global coconut milk products market has been estimated to be valued around US$ 885.9 Mn in 2018, which is projected to increase at a CAGR of 6.9%, to reach US$ 1,508.7 Mn in 2026. Read Report Overview: https://www.transparencymarketresearch.com/coconut-milk-products-market.html Coconut Milk
Clean Label Awareness to Drive Rice Syrup Market, notes TMR
The global rice syrup market is expected to experience steady growth, according to analysts at Transparency Market Research (TMR). Key worldwide production companies and product developers processing rice syrup focus on decreasing the concentration of arsenic by means of sophisticated methods of refining, without decreasing dietary importance. Because of increasing consumer demand, manufacturers are more likely to process organic rice syrup. The good alternative to honey by vegan customers is
Beta-Carotene Market Expected to Increase at a CAGR of 3.8% in Terms of Revenue …
Transparency Market Research (TMR) delivers detailed insights into the global beta-carotene market, in its upcoming outlook titled, ‘Beta-Carotene Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2019-2027‘. The global beta-carotene market is projected to register a CAGR of 3.5% in terms of value during the period of forecast, due to various factors influencing the market, regarding which, Transparency Market Research offers detailed insights. Read Report Overview: https://www.transparencymarketresearch.com/beta-carotene-market.html Asia Pacific

All 5 Releases


More Releases for FAP

Familial Adenomatous Polyposis (FAP) Therapeutics- Pipeline Analysis 2018
Familial adenomatous polyposis (FAP) is a genetic disorder, characterized by the development of adenomatous colon polyps in the intestinal tract, resulting in colon cancer. The disease is diagnosed when more than 100 adenomatous colon polyps are developed in a person. Download the sample report at: https://www.pharmaproff.com/request-sample/1025 A person with FAP is at a high risk of developing cancer of small intestines or stomach. This disease is categorized into three types including attenuated
Fibroblast Activation Protein Inhibitors Market to Witness a Pronounce Growth by …
Fibroblast activation protein (FAP) is a serine protein that is selectively expressed in pathologic sites in the adults making it a target specific site for many therapeutic agents. Fibroblast activation protein (FAP) is expressed during tissue remodeling stage in embryonic development. However, in adults, fibroblast activation protein (FAP) is expressed in specific sites like cancer, arthritis, inflammation, injury, pulmonary fibrosis, etc. Fibroblast activation protein is widely believed to be expressed
Fibroblast Activation Protein Inhibitors Market Dynamics, Forecast, Analysis and …
Fibroblast activation protein (FAP) is a serine protein that is selectively expressed in pathologic sites in the adults making it a target specific site for many therapeutic agents. Fibroblast activation protein (FAP) is expressed during tissue remodeling stage in embryonic development. However, in adults, fibroblast activation protein (FAP) is expressed in specific sites like cancer, arthritis, inflammation, injury, pulmonary fibrosis, etc. Fibroblast activation protein is widely believed to be expressed
Fibroblast Activation Protein Inhibitors Market with Current Trends Analysis, 20 …
Fibroblast activation protein (FAP) is a serine protein that is selectively expressed in pathologic sites in the adults making it a target specific site for many therapeutic agents. Fibroblast activation protein (FAP) is expressed during tissue remodeling stage in embryonic development. However, in adults, fibroblast activation protein (FAP) is expressed in specific sites like cancer, arthritis, inflammation, injury, pulmonary fibrosis, etc. Fibroblast activation protein is widely believed to be expressed
Fibroblast Activation Protein Inhibitors Market by Key Players, Growth, Regions …
Fibroblast activation protein (FAP) is a serine protein that is selectively expressed in pathologic sites in the adults making it a target specific site for many therapeutic agents. Fibroblast activation protein (FAP) is expressed during tissue remodeling stage in embryonic development. However, in adults, fibroblast activation protein (FAP) is expressed in specific sites like cancer, arthritis, inflammation, injury, pulmonary fibrosis, etc. Fibroblast activation protein is widely believed to be expressed
Fibroblast Activation Protein Inhibitors Market : Huge Opportunities Lie In Deve …
Fibroblast activation protein (FAP) is a serine protein that is selectively expressed in pathologic sites in the adults making it a target specific site for many therapeutic agents. Fibroblast activation protein (FAP) is expressed during tissue remodeling stage in embryonic development. However, in adults, fibroblast activation protein (FAP) is expressed in specific sites like cancer, arthritis, inflammation, injury, pulmonary fibrosis, etc. Fibroblast activation protein is widely believed to be expressed